Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 23,420
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 23,040
Intrexon Energy Partners, LLC | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		8,362
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Contract With Customer, Asset And Liability [Line Items]
Average Remaining Performance Period (Years)	2 years 6 months
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 8,362
Intrexon Energy Partners II, LLC | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		12,843
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Contract With Customer, Asset And Liability [Line Items]
Average Remaining Performance Period (Years)	3 years 2 months 12 days
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 12,843
Castle Creek Biosciences, Inc. | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		379
Castle Creek Biosciences, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Contract With Customer, Asset And Liability [Line Items]
Average Remaining Performance Period (Years)	3 months 18 days
Castle Creek Biosciences, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 17
Other | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 1,836
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Contract With Customer, Asset And Liability [Line Items]
Average Remaining Performance Period (Years)	3 years 1 month 6 days
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 1,818